Onvansertib Clinical Trials

4 actively recruiting trials across 4 locations

Also known as: 'PLK1 Inhibitor PCM-075, NMS-1286937, PCM 075, PCM-075, PLK-1 Inhibitor PCM-075, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 1 Inhibitor PCM-075

Filter by location:

Kansas City, Kansas1 trial

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

The University of Kansas Cancer Center, Westwood Campus

Phase 1/2

Baltimore, Maryland1 trial

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

University of Maryland Greenebaum Comprehensive Cancer Center

Phase 2

Rochester, Minnesota1 trial

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Mayo Clinic in Rochester

Phase 1

Portland, Oregon1 trial

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

OHSU Knight Cancer Institute

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.